Nuclear Medicine Market Essentials 2017

Includes cyclotrons, cameras, brachytherapy seeds and microspheres
MEDraysintell releases its first Nuclear Medicine Market Essentials report with key facts and figures.

A key tool to help the healthcare industry or for the financial community (investors, investment bankers and M&A professionals)
Nuclear Medicine

- Nuclear medicine remains a niche market representing less than 1% of the global pharmaceutical industry, but new opportunities lie ahead, especially in radiotherapeutics
  - Five new radiotherapeutics with a blockbuster potential (annual sales potential ≥US$ 1 billion) to reach the market before 2025
  - Opportunities exist for larger groups or investors to finance such development, to merge with key partners and/or to acquire companies.

- The number of medical cyclotrons are expected to grow with the emergence of the Asian and South American markets and the need of tools for new proprietary tracers.
Nuclear Medicine

- Almost 100 radiopharmaceuticals are currently marketed around the World, but some are only available locally.

- The top 15 radiopharmaceuticals account for over 20% of the world market.

- $^{99m}$Tc based radiopharmaceuticals account for over 50% of the world market.

- Innovative solutions and additional sources will also emerge to cover the need for $^{99}$Mo.

- The year 2016 was also the turning point for the introduction of new proprietary fluorinated molecules and novel radiodiagnostics based on $^{68}$Ga.
Need for factual information

- MEDraysintell Market Essentials Report is the solution to gain an expert view on the Global Nuclear Medicine industry, with accurate facts in a condensed document and a real added value for the reader.

- To advice non-industry insiders on the potential for investments, merger and acquisitions (M&A), technology and market development existing in this healthcare technology using radiation for diagnosis and therapy.
Need for factual information

- The “Nuclear Medicine Market Essentials” includes over 40 tables and figures covering the market, key drivers, vendors, products (radiodiagnostics and radiotherapeutics) of interest for the coming decade, as well as companies to monitor.

- It covers not only radiopharmaceuticals, but also equipment (cyclotrons and cameras), as well as some aspects of the brachytherapy market sometimes overlapping with the nuclear medicine specialty (microspheres and seeds).
An opposing view to non-experts reports

- Regrettably there are too many misleading, outdated and confusing information on Nuclear Medicine from many recent articles and market reports written by non-experts.

- MEDraysintell identified recent publications reporting about confusing information on a new potential Molybdenum-99 shortage, or unrealistic projections for the PET versus SPECT market, while not recognizing the growth in radiotherapeutics too often erroneously associated with brachytherapy.
How to Order

To obtain a detailed table of contents and sample pages and to order, send an e-mail with your contact details - click the button
About MEDraysintell

More than 40 years of experience in
- Nuclear Medicine
- Particle therapy
- Brachytherapy

MEDraysintell provides strategic intelligence for the radiation healthcare to help clients understand
- Markets
- Competitive environment
- Potential for M&A
- Technology development

The most comprehensive set of reports & directories with over 1,900 pages of unrivaled intelligence, covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment.
Contact

- MEDraysintell reports and directories can be customized to specific areas or modalities
- Sample pages and complete table of contents are available upon request
- MEDraysintell also welcomes your requests for specific intelligence needs

Paul-Emmanuel Goethals, MBA
Louvain-la-Neuve, Belgium
peg@medraysintell.com
Phone: +32 491 080 968

Dr. Richard Zimmermann, PhD
Lalaye, France
rz@medraysintell.com
Phone: +33 6 82 80 06 00
Disclaimer

This MEDraysintell presentation and information contained herein, coming from several MEDraysintell’s reports is believed to be accurate at the time of publication; it has been gathered in good faith from several sources, but the authors are not in a position to guarantee its accuracy. The authors do not accept any responsibility for the content of this report/presentation. Information contained herein may be of a speculative nature and must be used with careful consideration. The authors assume no liability for any loss or damage – including but not limited to lost time, lost money, lost profits, lost customers – that may result from any use of the information or actions taken based on any analyses, projections, discussions, recommendations, or conclusions of any kind presented in this report/presentation.